Sunday, February 28, 2021

4 more Covid vaccines in different stages of trial: SII

- Advertisement -

serum institutrNew Delhi, Jan 17 (IANS) Apart from Covishield, the Serum Institute of India (SII) is working on four more vaccines against the novel coronavirus, according to Suresh Jadhav, executive director at one of the world’s largest vaccine manufacturers.

Jadhav informed during a webinar that the firm has been working on five vaccines against the novel coronavirus, including the Covishield which got approval for emergency use roll-out for mass immunization drive began on Saturday.

“For one (vaccine) we have received emergency approval, three others are in different stages of clinical studies while one is in the pre-clinical stage of the trial,” he said.

The SII has partnered with Novavax Inc to manufacture its potential Covid-19 vaccine for India and other countries.

Under an agreement with the US drug developer, the Pune based drugmaker will develop two hundred crore doses of Novavax’s vaccine candidate annually.

READ ALSO:  Inoculation not only option, follow health norms: Bengal docs

The drugmaker will also manufacture the antigen component of the vaccine.

The SII has also partnered with the US-based Codagenix to manufacture and supply its coronavirus vaccine.

The firm’s first Covid vaccine is developed from the masterseed of AstraZeneca/Oxford University’s vaccine against the disease.

It was approved by India’s drug regulator on January 3 for emergency use authorization alongwith Bharat Biotech’s Covaxin.

However, both the drugmakers are being criticised for less transparent data in their clinical trials and receiving the approvals without completing the due process of drug licencing.

Commenting on the criticism the vaccine manufacturers have been receiving for getting approvals without completing all the trials, Jadhav said that such chances have been taken earlier as well.

READ ALSO:  Mumbai-Ahmedabad bullet train project progressing well: Railways

“It is not the only time when humanity has taken the chances. Four years back, there was an outbreak of Ebola in Africa and its vaccine by a Canadian pharmaceutical firm which had only completed the phase 1 and undergoing the phase 2 trial, was approved by the World Health Organization (WHO). The risk paid off and the vaccine helped in controlling the Ebola there,” Jadhav added.

READ ALSO:  3rd phase of Vax drive to cover those above 50, beginning March: Harsh Vardhan

“In 2009 when the H1N1 pandemic flu struck, we took 1.5 years to develop and receive the approval for the vaccine against it after completing all the stages of clinical trials but the drug manufacturers in the West marketed such products in less than seven months then. Nobody questioned them then. Then why this sudden hullabaloo now?” he queried.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News


Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

UPA may form govt in Tamil Nadu with 150+ seats win

New Delhi, Feb 27 (IANS) The United Progressive Alliance (UPA) is likely to sweep the Tamil Nadu assembly with a projected win on 158...

Assam: NDA’s vote share to rise, may win 72 seats

New Delhi, Feb 27 (IANS) The National Democratic Alliances (NDA) vote share is likely to increase by 1.9 per cent in the upcoming Assam...

Survey: Modi in Bengal, Rahul in Kerala most suited for PM

New Delhi, Feb 27 (IANS) Despite being the top choice as a Chief Minister in West Bengal, the voter in the state prefers Narendra...

Pink ball gives edge to bowlers on bowler-friendly pitches: Ashwin

By Khurram Habib (IANS): India off-spinner Ravichandran Ashwin on Saturday said that 'pink-ball' Test cricket was still evolving and teams were still getting to grips...